Medigus Announces Corporate Rebranding Changes Name to Xylo Technologies Ltd. to Reflect Core Values of Its Business
Medigus Announces Corporate Rebranding Changes Name to Xylo Technologies Ltd. to Reflect Core Values of Its Business
Medigus' Nasdaq trading symbol will change to XYLO on April 18, 2024
Medigus 的納斯達克交易代碼將於 2024 年 4 月 18 日更改爲 XYLO
Tel Aviv, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ: MDGS) ("Medigus" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today a corporate rebranding to reflect current focus in innovation technologies. At the heart of this rebranding is a change of the Company's name to Xylo Technologies Ltd. to embody its corporate vision and core values.
以色列特拉維夫，2024年4月9日（環球新聞專線）——從事先進創新技術的科技型公司Medigus Ltd.（納斯達克股票代碼：MDGS）（“Medigus” 或 “公司”）今天宣佈進行企業品牌重塑，以反映當前對創新技術的關注。此次品牌重塑的核心是將公司更名爲Xylo Technologies Ltd.，以體現其企業願景和核心價值觀。
The rebranding includes a new name and an update to the Company's corporate logo, as well as a new website.
品牌重塑包括新名稱、公司徽標更新以及新網站。
In addition, the Company's Nasdaq trading symbols will change to XYLO. The Company will begin trading on the Nasdaq Capital Market ("Nasdaq") under its new name "Xylo Technologies Ltd." and new trading symbol "XYLO" upon the opening of the market on April 18, 2024.
此外，該公司的納斯達克交易代碼將更改爲XYLO。該公司將於2024年4月18日開市後，以新名稱 “Xylo Technologies Ltd.” 和新的交易代碼 “XYLO” 開始在納斯達克資本市場（“納斯達克”）上交易。
About Medigus
關於 Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle markets. Medigus' affiliations in the medical solutions arena include ownership in Polyrizon Ltd. The Company's affiliates in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd., and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd., and Revoltz Ltd., by way of Fuel Doctor Holdings, Inc. are also part of the Company's portfolio of technology solution providers. Medigus is traded on Nasdaq Capital Market. To learn more about Medigus' advanced technologies, please visit .
總部位於以色列的Medigus Ltd.（納斯達克股票代碼：MDGS）是一家專注於創新增長夥伴關係的科技公司，主要涉及先進的醫療解決方案、數字商務和電動汽車市場。Medigus在醫療解決方案領域的關聯公司包括Polyrizon Ltd的所有權。該公司在數字商務領域的子公司包括Gix互聯網有限公司、傑夫斯品牌有限公司和Eventer Technologies Ltd.。在電動汽車市場，Charging Robots Ltd.和通過Fuel Doctor Holdings, Inc.旗下的Revoltz Ltd.也是該公司技術解決方案提供商組合的一部分。Medigus在納斯達克資本市場上市。要了解有關 Medigus 先進技術的更多信息，請訪問 。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Medigus' current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release.
本新聞稿包含1995年《私人證券訴訟改革法》和其他聯邦證券法的 “安全港” 條款所指的前瞻性陳述。諸如 “期望”、“預期”、“打算”、“計劃”、“相信”、“尋求”、“估計” 之類的詞語以及此類詞語的類似表述或變體旨在識別前瞻性陳述。由於此類聲明涉及未來事件並基於Medigus當前的預期，因此它們受到各種風險和不確定性的影響，實際業績、業績或成就可能與本新聞稿中的聲明中描述或暗示的結果存在重大差異。
The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Medigus undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Medigus is not responsible for the contents of third-party websites.
Company Contact:
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
本新聞稿中包含或暗示的前瞻性陳述受其他風險和不確定性的影響，包括向美國證券交易委員會提交的任何文件中討論的風險和不確定性。除非法律另有要求，否則Medigus沒有義務公開發布對這些前瞻性陳述的任何修訂，以反映本聲明發布之日之後的事件或情況或反映意外事件的發生。爲方便起見，我們提供了網站引用和鏈接，此類網站上包含的信息未以引用方式納入本新聞稿。Medigus 對第三方網站的內容不承擔任何責任。
公司聯繫人：
塔利第納爾
首席財務官
+972-8-6466-880
ir@medigus.com
Investor Relations Contact:
Michal Efraty
Investor Relations, Israel
+972-(0)52-3044404
michal@efraty.com
投資者關係聯繫人：
邁克爾·埃弗拉蒂
投資者關係，以色列
+972-(0) 52-3044404
michal@efraty.com
譯文內容由第三人軟體翻譯。